Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Pfizer Inc (PFE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 259,009,376
  • Shares Outstanding, K 5,952,870
  • Annual Sales, $ 52,546 M
  • Annual Income, $ 21,308 M
  • 36-Month Beta 0.88
  • Price/Sales 4.90
  • Price/Cash Flow 11.52
  • Price/Book 3.59

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 0.64
  • Number of Estimates 4
  • High Estimate 0.66
  • Low Estimate 0.63
  • Prior Year 0.62
  • Growth Rate Est. (year over year) +3.23%

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.66 +6.05%
on 10/25/18
44.61 -0.96%
on 11/09/18
-0.32 (-0.72%)
since 10/19/18
3-Month
41.09 +7.52%
on 08/31/18
45.81 -3.56%
on 10/09/18
+2.09 (+4.97%)
since 08/17/18
52-Week
33.20 +33.07%
on 02/09/18
45.81 -3.56%
on 10/09/18
+8.81 (+24.91%)
since 11/17/17

Most Recent Stories

More News
Pfizer (PFE) Gains As Market Dips: What You Should Know

Pfizer (PFE) closed the most recent trading day at $44.20, moving +1.57% from the previous trading session.

PFE : 44.18 (+1.54%)
Amgen's Blincyto Gets Positive CHMP Opinion for Line Extension

Amgen's (AMGN) leukemia drug, Blincyto receives positive CHMP opinion for label expansion to include minimal residual disease.

GILD : 68.01 (-1.72%)
AMGN : 194.91 (+0.38%)
PFE : 44.18 (+1.54%)
ALXN : 115.06 (-3.00%)
Drug Pricing Resurfaces, Pfizer to Raise Cost of 41 Drugs

Per a Wall Street report, Pfizer (PFE) plans to increase the list prices of its 41 prescription drugs in 2019.

MRK : 76.35 (+0.38%)
NVS : 88.31 (+0.64%)
AMGN : 194.91 (+0.38%)
PFE : 44.18 (+1.54%)
The Zacks Analyst Blog Highlights: Pfizer, Cisco, Southern, SunTrust Banks and AmerisourceBergen

The Zacks Analyst Blog Highlights: Pfizer, Cisco, Southern, SunTrust Banks and AmerisourceBergen

ABC : 90.82 (+2.33%)
CSCO : 45.75 (-1.29%)
STI : 63.09 (+0.69%)
SO : 47.04 (+0.32%)
PFE : 44.18 (+1.54%)
Today's Research Reports on Trending Tickers: Facebook and Pfizer

NEW YORK, NY / ACCESSWIRE / November 19, 2018 / Pfizer and Facebook were both in deep water last week. Pharma giant Pfizer decided to increase the prices of 41 drugs according to the WSJ with the price...

PFE : 44.18 (+1.54%)
Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer

Not intended for UK-based media

PFE : 44.18 (+1.54%)
MKKGY : 22.1700 (-0.83%)
uniQure Up on Positive Data From Mid-Stage Hemophilia Study

uniQure's (QURE) gene therapy candidate, AMT-061, demonstrates significant improvement in hemophilia B patients in a mid-stage study. Investors' sentiment improves.

QURE : 28.94 (-9.11%)
ONCE : 37.15 (-5.16%)
PFE : 44.18 (+1.54%)
BMY : 53.48 (-1.09%)
Lilly Offers Updates on Progress of Headache Disorder Drugs

Eli Lilly (LLY) files NDA with FDA for migraine candidate, lasmiditan. FDA grants Breakthrough Therapy status to Emgality for episodic cluster headache indication.

LLY : 115.81 (+1.74%)
TEVA : 22.00 (-1.12%)
AMGN : 194.91 (+0.38%)
PFE : 44.18 (+1.54%)
Sangamo's Shares Drop on Rating Downgrade, Pipeline Woes

Sangamo Therapeutics (SGMO) postpones data presentation from its haemophilia study, following dose escalation recommendation from an independent committee. This raises concerns about its development.

SGMO : 10.74 (-4.19%)
JPM : 110.83 (+0.76%)
GILD : 68.01 (-1.72%)
PFE : 44.18 (+1.54%)
Shire's Filing Accepted by FDA for Gattex's Label Expansion

The FDA accepts Shire's (SHPG) sNDA and is expected to take action in March 2019.

LLY : 115.81 (+1.74%)
SHPG : 175.60 (+0.01%)
PFE : 44.18 (+1.54%)
BMY : 53.48 (-1.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade PFE with:

Business Summary

Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional...

See More

Key Turning Points

2nd Resistance Point 44.75
1st Resistance Point 44.46
Last Price 44.18
1st Support Level 43.70
2nd Support Level 43.23

See More

52-Week High 45.81
Last Price 44.18
Fibonacci 61.8% 40.99
Fibonacci 50% 39.51
Fibonacci 38.2% 38.02
52-Week Low 33.20

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar